Here are the 10-Q quarterly reports from ESSA Pharma Inc. (EPIX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EPIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EPIX filings page.
ESSA Pharma (EPIX) reported interim results as of June 30, 2025 showing a strong cash position and a major strategic shift. The company held $85.95 million in cash and $23.67 million in short-term U.S. Treasury securities, giving working capital of $108.90 million and total assets of $110.50 million. ESSA recorded a net loss of $18.91 million for the nine months ended June 30, 2025 and an accumulated deficit of $226.91 million. In October 2024 ESSA terminated clinical trials of its lead candidate, masofaniten (EPI-7386), and withdrew related IND/CTA filings. Subsequent to the quarter, ESSA entered a Business Combination Agreement with XenoTherapeutics under which shareholders are currently estimated to receive approximately US$1.91 per share plus one non-transferable contingent value right (CVR) per share entitling holders to a pro rata portion of up to US$2.95 million (up to US$0.06 per CVR). The Transaction requires court and shareholder approvals and is expected to close in the second half of 2025.